2021
This morning, at the 23rd International AIDS Conference, our collaborator Martina Penazzato provided a plenary speech on pediatric HIV. We met with her and asked for her thoughts on what urgent action we need to take to end AIDS in children.
2020
Penta has been invited to run a one-day session at the Republican Hospital of Infectious Diseases, St Petersburg conference on ‘Actual problems of HIV Infection: Mother and Child’ on Tuesday 15th September.
2020
Last Patient Last Visit (LPLV) completed for the Penta 17 Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (SMILE) trial.
The Penta sponsored trial,
2020
Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. Food and Drug Administration (FDA) of the adult formulation for children weighing ≥20kg and dolutegravir (DTG) dispersible tablets for children of 4 weeks of age and older.
2020
Join the 6th Workshop on Children and Adolescents HIV-exposed and Uninfected (HEU) at 3pm (CEST) on 1st July 2020.
The workshop is part of the pre-conference programme of the International AIDS virtual conference 2020.
2020
The 10th International Workshop on HIV & Women is in Boston on 6 – 7 March 2020, just prior to CROI.
This is an outstanding opportunity for health care providers,
2020
Just published – data on T & B cell memory and T cell function in early-treated children in the Journal of Immunology and AIDS.
2019
Today we celebrate Human’s Right Day: this year’s theme is “Youth Standing Up for Human Rights”.
School HIV-prevention campaigns in Africa are often designed to frighten children.
2019
Picturing Health has created the first video in a three part series of adolescent films about growing up with HIV. This series of short films tackles the issue of dealing with disclosure and the impact a child being told they are HIV positive.
2019
The theme of this year’s World AIDS Day, which we commemorate today, is “Communities make the difference“. Today we highlight the role of communities in ensuring that AIDS remains at the top of the political agenda.
2019
The many challenges of developing drugs appropriately formulated for children are compounded by a series of market factors that make these efforts costly and complex, discouraging drug manufacturers – especially generic drug manufacturers – from prioritizing investments in new paediatric treatment options.
2018
Although the number of new HIV infections has continued to decline globally, and the overall level of HIV treatment is high, progress is far slower than what is required to reach the 2020 milestone of less than 500,000 new infections.